Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
AstraZeneca
Merck
McKinsey
Harvard Business School

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR EGRIFTA


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Egrifta

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00608023 ↗ TH9507 Extension Study in Patients With HIV- Associated Lipodystrophy Completed Theratechnologies Phase 3 2007-08-01 HIV lipodystrophy affects a significant proportion of patients treated with combination antiretroviral therapy (ART) and is characterized by excess visceral fat accumulation, loss of extremity and subcutaneous fat, in association with dyslipidemia and insulin resistance. Data from the first Phase 3 multicenter, randomized, placebo-controlled trial demonstrated that daily administration of 2mg TH9507, a growth hormone releasing factor (GRF), to HIV- infected patients with excess of abdominal fat accumulation for 26 weeks resulted in decreases in visceral adipose tissue (VAT) and trunk fat, with lesser changes in limb fat and subcutaneous adipose tissue (SAT). The present study is aimed at confirming the observations made during the first Phase 3 study.
NCT01579695 ↗ Long-term Observational Study in HIV Subjects Exposed to EGRIFTA® Terminated Theratechnologies 2013-02-01 The purpose of this observational, 10-year, prospective cohort study is to assess the potential safety concerns of long-term exposure to EGRIFTA® in HIV-infected subjects with abdominal lipohypertrophy compared with a similar group of subjects not exposed to EGRIFTA®.
NCT01591902 ↗ Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA® Terminated Theratechnologies Phase 4 2012-06-01 To show the non-inferiority of EGRIFTA® vs. placebo in the development or progression of Diabetic Retinopathy in HIV-infected subjects with concomitant abdominal lipohypertrophy and Type 2 diabetes mellitus (T2DM).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Egrifta

Condition Name

Condition Name for Egrifta
Intervention Trials
HIV 3
Lipodystrophy 2
Mild Cognitive Impairment 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Egrifta
Intervention Trials
Lipodystrophy 3
Mild Cognitive Impairment 2
HIV-Associated Lipodystrophy Syndrome 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Egrifta

Trials by Country

Trials by Country for Egrifta
Location Trials
United States 48
Canada 4
Spain 1
France 1
Belgium 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Egrifta
Location Trials
Texas 4
California 4
Maryland 3
Washington 3
New York 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Egrifta

Clinical Trial Phase

Clinical Trial Phase for Egrifta
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Egrifta
Clinical Trial Phase Trials
Completed 4
Recruiting 3
Terminated 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Egrifta

Sponsor Name

Sponsor Name for Egrifta
Sponsor Trials
Theratechnologies 4
Johns Hopkins University 2
Massachusetts General Hospital 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Egrifta
Sponsor Trials
Other 9
Industry 4
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Baxter
Colorcon
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.